Medtronic plc (MDT) FY2025 Annual P&L / Income Statement

2024-04-27 to 2025-04-25

Swipe to see the full flow
Medtronic plc (MDT) FY2025 Annual P&L / Income StatementIncome statement for 2024-04-27 through 2025-04-25. View: Segments by Subsegments. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUE RECONCILIATIONREVENUEGROSSOPERATINGPRE-TAXNETMedical Surgical - Surgical & EndoscopyCardiovascular - Cardiac Rhythm & Heart FailureNeuroscience - Cranial & Spinal TechnologiesCardiovascular - Structural Heart & AorticNeuroscience - Specialty TherapiesDiabetesCardiovascular - Coronary & Peripheral VascularNeuroscience - NeuromodulationMedical Surgical - Acute Care & MonitoringOther operating segmentNet salesRevenue before reconciliation (calculated)Components above reported revenue (calculated)Gross profit (calculated)Cost of products sold, excluding amortization of intangible assetsOperating profitOperating costs, net of other operating income (calculated)Selling, general, and administrative expenseResearch and development expenseAmortization of intangible assetsCertain litigation charges, netRestructuring charges, netOther operating (income) expense, netIncome before income taxesOther income (expense), net (calculated)Net incomeIncome tax provisionRevenue before reconciliation (calculated)Revenue beforereconciliation(calculated)$33.63 BGross profit (calculated)Gross profit(calculated)$21.91 BNet salesNet sales$33.54 BOperating profitOperating profit$5.96 BIncome before income taxesPretax income$5.63 BNet incomeNet income$4.69 BMedical Surgical - Surgical & EndoscopyMedical Surgical -Surgical & Endoscopy$6.50 BOperating costs, net of other operating income (calculated)Operating costs,net (calculated)$15.95 BCardiovascular - Cardiac Rhythm & Heart FailureCardiovascular -Cardiac Rhythm& Heart Failure$6.39 BIncome tax provisionIncome taxes$936.00 MOther income (expense), net (calculated)Other income,net (calculated)−$327.00 MSelling, general, and administrative expenseSelling, general, andadministrative expense$10.85 BNeuroscience - Cranial & Spinal TechnologiesNeuroscience - Cranial& Spinal Technologies$4.97 BCost of products sold, excluding amortization of intangible assetsCost of products sold$11.63 BCardiovascular - Structural Heart & AorticCardiovascular- StructuralHeart & Aortic$3.55 BResearch and development expenseResearch anddevelopment expense$2.73 BAmortization of intangible assetsAmortization of intangible assets$1.81 BNeuroscience - Specialty TherapiesNeuroscience -Specialty Therapies$2.94 BCertain litigation charges, netCertain litigation charges, net$317.00 MDiabetesDiabetes$2.76 BComponents above reported revenue (calculated)Components abovereported revenue(calculated)−$88.00 MRestructuring charges, netRestructuring charges, net$267.00 MCardiovascular - Coronary & Peripheral VascularCardiovascular- Coronary &Peripheral Vascular$2.54 BOther operating (income) expense, netOther operating(income) expense, net−$23.00 MNeuroscience - NeuromodulationNeuroscience -Neuromodulation$1.93 BMedical Surgical - Acute Care & MonitoringMedical Surgical- Acute Care& Monitoring$1.91 BOther operating segmentOther operatingsegment$137.00 M
Chart details

Medtronic plc (MDT) FY2025 Annual P&L / Income Statement

Income statement for 2024-04-27 through 2025-04-25. View: Segments by Subsegments. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net sales
33,537,000,000 US dollars
Cost of products sold, excluding amortization of intangible assets
11,632,000,000 US dollars
Gross profit (calculated)
21,905,000,000 US dollars
Operating costs, net of other operating income (calculated)
15,949,000,000 US dollars
Operating profit
5,955,000,000 US dollars
Other income (expense), net (calculated)
negative 327,000,000 US dollars
Income before income taxes
5,628,000,000 US dollars
Income tax provision
936,000,000 US dollars
Net income
4,691,000,000 US dollars
Diabetes
2,755,000,000 US dollars
Other operating segment
137,000,000 US dollars
Cardiovascular - Cardiac Rhythm & Heart Failure
6,392,000,000 US dollars
Cardiovascular - Coronary & Peripheral Vascular
2,535,000,000 US dollars
Cardiovascular - Structural Heart & Aortic
3,554,000,000 US dollars
Medical Surgical - Acute Care & Monitoring
1,909,000,000 US dollars
Medical Surgical - Surgical & Endoscopy
6,498,000,000 US dollars
Neuroscience - Cranial & Spinal Technologies
4,973,000,000 US dollars
Neuroscience - Neuromodulation
1,932,000,000 US dollars
Neuroscience - Specialty Therapies
2,940,000,000 US dollars
Research and development expense
2,732,000,000 US dollars
Selling, general, and administrative expense
10,849,000,000 US dollars
Amortization of intangible assets
1,807,000,000 US dollars
Restructuring charges, net
267,000,000 US dollars
Certain litigation charges, net
317,000,000 US dollars
Other operating (income) expense, net
negative 23,000,000 US dollars
Revenue before reconciliation (calculated)
33,625,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
Components above reported revenue (calculated)
negative 88,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
  • Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
  • Of which attributable to Medtronic plc: $4.66 B; to noncontrolling interests: $29.00 M.
  • The amounts that make up operating profit come to $5,956.00 M and operating profit is $5,955.00 M; the $1.00 M difference is within the rounding of the filed amounts.
  • The amounts that make up net income come to $4,692.00 M and net income is $4,691.00 M; the $1.00 M difference is within the rounding of the filed amounts.
Medtronic plc (MDT) FY2025 Annual P&L / Income Statement Sankey chart, Segments by Subsegments view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

65.3%

Gross profit / revenue

Operating margin

17.8%

Operating profit / revenue

Cash conversion

150.2%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!